Amneal Adds Another Complex Generic With TobraDex Approval
Expands Portfolio With Dexamethasone/Tobramycin Ophthalmic Suspension
Amneal has broadened its complex generics portfolio by gaining FDA approval for its generic version of ophthalmic combination medicine TobraDex.
You may also be interested in...
The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.
Amneal is setting its sights on the migraine and cluster headache market in the US with a new hybrid 505(b)(2) filing for a dihydroergotamine autoinjector.
Amneal will take a majority stake in Kashiv Specialty Pharmaceuticals after striking a deal worth potentially more than $100m for a 98% stake in the hybrid 505(b)(2) and complex generics specialist.